TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04183205

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: LDAEP
Description: This is an ERP task in which participants hear a series of tones ranging from 74dB to 104dB and electrophysiological activity is measured throughout. For each participant average P2 scores are derived for the 74dB tones, 84dB tones, 94dB tones, and 104dB tones. Then, LDAEP is defined as the slope of these average P2 scores.
Study: NCT02027961

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Intravenous dose of 3 or 10 mg/kg durvalumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Oral dose of 150 mg dabrafenib capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Oral dose of 150 mg dabrafenib capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Oral dose of 2 mg trametinib tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Oral dose of 2 mg trametinib tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Oral dose of 2 mg trametinib tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Oral dose of 2 mg trametinib tablet.
Study: NCT05521620

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The father-friendly NICU
Description: * Fathers have skin-to-skin contact with their infants~* Fathers participate in important situations~* Fathers receive information and guidance directly~* Both parents participate in meaningful conversations~* The department organize mother and father groups~* The families have the opportunity to have a close family member to support them~* Older siblings have the opportunity to stay overnight.~* The department offer counseling by a social worker
Study: NCT00142935

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-release Initiation of MMT
Description: Participants assigned to arm 1 will undergo extensive assessment (physical, medical history, drug use and treatment history) prior to initiating treatment. MMT will begin 1-30 days prior to release from incarceration. MMT first dose will begin at 5 mg with 2 mg increase per day until release or therapeutic dose of 60-120 mg is achieved. Daily observation by dosing nurses and twice weekly symptom review by Research Assistant will occur. Additionally, participants assigned to Arm 1 will have all logistical arrangements made for entry into a community methadone clinic program within 24 hours of release from incarceration. The study will fully pay for MMT for 12 weeks and half the costs of treatment for the next 12 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Post Release Initiation of MMT.
Description: Participants assigned to Arm 2 will have all logistical arrangements made for entry into a community methadone clinic program within 24-48 hours of release from incarceration. The study will fully pay for MMT for 12 weeks and half the costs of treatment for the next 12 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Plus
Description: Participants assigned to Arm 3 will not begin treatment prior to release from incarceration or have treatment paid for by the study. However, study staff will work with participants to identify ways to pay for treatment, including assisting with medicaid applications, etc. Further, the study will make the logistical arrangements for entering treatment if participant has a means to finance MMT.
Study: NCT00062062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study: NCT03333655

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biopsy
Description: Participants who received or are receiving CPI therapy for metastatic cancer or hematologic malignancies.
Study: NCT02701361

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mobile mindfulness
Description: Receives audiovisual mindfulness content via internet plus call depending on symptoms or request.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standard mindfulness
Description: Receives weekly calls from mindfulness expert for 4 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: education
Description: Receives web-based content about critical illness topics. Also receives two calls from study team to describe materials and answer questions about materials.
Study: NCT04591301

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HEC113995 PA•H2O tablets
Description: Each dose of HEC113995 PA•H2O tablets will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC113995 PA•H2O tablets
Description: Each dose of HEC113995 PA•H2O tablets will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HEC113995 PA•H2O tablets
Description: Each dose of HEC113995 PA•H2O tablets will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HEC113995 PA•H2O tablets
Description: Each dose of HEC113995 PA•H2O tablets will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HEC113995 PA•H2O tablets
Description: Each dose of HEC113995 PA•H2O tablets will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HEC113995 PA•H2O tablets
Description: Each dose of HEC113995 PA•H2O tablets will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HEC113995 PA•H2O tablets
Description: Each dose of HEC113995 PA•H2O tablets will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Description: Placebo tablets will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.
Study: NCT04898803

Intervention type: OTHER
Intervention: conventional DGVS training
Description: see above

Intervention type: OTHER
Intervention: extended simulator training
Description: see above
Study: NCT03370055

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: LeucoPatch®
Description: LeucoPatch® is an elastic membrane produced by the patients own venous blood by centrifugation, and one or two is placed on the wound once a week The LeucoPatch® consist of the fibrin Leucocytes and growth factors from the patients own blood

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LeucoPatch®
Description: LeucoPatch® is an elastic membrane produced by the patients own venous blood by centrifugation, and one or two is placed on the wound once a week The LeucoPatch® consist of the fibrin Leucocytes and growth factors from the patients own blood

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control,
Description: Usual wound care in a specialized clinic

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control,
Description: Usual wound care in a specialized clinic
Study: NCT00975806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide MTD mg by mouth (PO) daily for Days 1- 21 in combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide MTD mg by mouth (PO) daily for Days 1- 21 in combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib 37.5 mg PO daily on days 1-21 of each 21-day cycle in Cohort A or on days 1-14 in Cohorts F and G

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib 37.5 mg PO daily on days 1-21 of each 21-day cycle in Cohort A or on days 1-14 in Cohorts F and G
Study: NCT03775447

Intervention type: PROCEDURE
Intervention: Lumbar Puncture
Description: Lumbar Puncture for collection of Cerebrospinal Fluids

Intervention type: PROCEDURE
Intervention: Lumbar Puncture
Description: Lumbar Puncture for collection of Cerebrospinal Fluids
Study: NCT04599582

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hip Arthroplasty
Description: Patients are operated with hip replacement.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hip Arthroplasty
Description: Patients are operated with hip replacement.
Study: NCT04183205

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo pills of the same size, color and taste as the active drug will be administered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo pills of the same size, color and taste as the active drug will be administered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sertraline
Description: Sertraline is an FDA approved SSRI for treatment of PTSD.
Study: NCT00807846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib 50 mg or 100 mg PO BID for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: Naproxen 7.5 mg/kg PO BID \[maximum of 500 mg BID\] for 6 weeks
Study: NCT03340181

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RIPC
Description: 4 cycles of 5-min ischemia(using a blood pressure cuff inflated to 40mmHg over the patient's basic blood pressure) and 5-min repercussion are done on an upper limb before skin incision.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: RIPC
Description: 4 cycles of 5-min ischemia(using a blood pressure cuff inflated to 40mmHg over the patient's basic blood pressure) and 5-min repercussion are done on an upper limb before skin incision.
Study: NCT02621268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: Infusion of ICG 24 hours prior to surgery
Study: NCT03890887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1291583
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Oral solution
Study: NCT01290081

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Case management approach in referral to health care services
Description: Case management intervention aimed at increasing TB screening and treatment entry among injecting drug users referred from a methadone drug treatment program

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Case management approach in referral to health care services
Description: Case management intervention aimed at increasing TB screening and treatment entry among injecting drug users referred from a methadone drug treatment program
Study: NCT00102453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Pentoxifylline dosing: 20mg/Kg/day in a 20 mg/mL solution. Maximum dose of 1200mg/day. Dosing split into two equal parts taken morning and night with food.
Study: NCT02391506

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cartiva
Description: Cartiva Synthetic Cartilage Implant
Study: NCT00303108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin
Description: 30 mg/m2 IV on Day 1 of each 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC=5 on Day 1 of each 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: 4 mg/kg on Days 1 and 15 of each cycle(loading dose of 8 mg/kg on Day 1 of Cycle 1 only)
Study: NCT00756587

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cup Feeding
Description: using a cup feeding technique for feeding the preterm infants during NICU stay

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bottle Feeding
Description: receiving all feeding by bottle
Study: NCT03492463

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch
Description: Participants will wear the nicotine patch daily while switching from cigarette use to use of e-cigarettes for eight weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch
Description: Participants will wear the nicotine patch daily while switching from cigarette use to use of e-cigarettes for eight weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo patch
Description: Participants will wear the placebo patch daily while switching from cigarette use to use of e-cigarettes for eight weeks.
Study: NCT03511885

Intervention type: OTHER
Intervention: There is no intervention
Study: NCT00513617

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arginine
Description: Depending on the weight of the child or adult, the patients took any where between 4-10 capsules 2 times a day. Patients weighing less than 45 kilograms were on the low dose active (or placebo) so the capsules were smaller. Patients greater than or equal to 45 kgs were on the high dose active or placebo, so these capsules were larger.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arginine
Description: Depending on the weight of the child or adult, the patients took any where between 4-10 capsules 2 times a day. Patients weighing less than 45 kilograms were on the low dose active (or placebo) so the capsules were smaller. Patients greater than or equal to 45 kgs were on the high dose active or placebo, so these capsules were larger.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Depending on the weight of the child or adult, the patients took any where between 4-10 capsules 2 times a day. Patients weighing less than 45 kilograms were on the low dose active (or placebo) so the capsules were smaller. Patients greater than or equal to 45 kgs were on the high dose active or placebo, so these capsules were larger.
Study: NCT01151319

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdV63.HIVconsv low dose.
Description: Attenuated chimp adenovirus. 5x10\^9 virus particles.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdV63.HIVconsv high dose.
Description: Attenuated chimp adenovirus at 5x10\^10 virus particles.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdV63.HIVconsv high dose.
Description: Attenuated chimp adenovirus at 5x10\^10 virus particles.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdV63.HIVconsv high dose.
Description: Attenuated chimp adenovirus at 5x10\^10 virus particles.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pSG2.HIVconsv
Description: DNA at 4mg per dose.
Study: NCT03577457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATD treatment
Description: oral administration of ATD (75.2g) (Acute Tryptophan Depletion)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal placebo treatment (placebo-control for oxytocin)
Description: intranasal administration of placebo nasal spray
Study: NCT01151319

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pSG2.HIVconsv
Description: DNA at 4mg per dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA.HIVconsv
Description: Attenuated poxvirus at 4x10\^8 plaque forming units per dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA.HIVconsv
Description: Attenuated poxvirus at 4x10\^8 plaque forming units per dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA.HIVconsv
Description: Attenuated poxvirus at 4x10\^8 plaque forming units per dose.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phosphate buffered saline

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phosphate buffered saline

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phosphate buffered saline
Study: NCT03808584

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: 4 specific core muscle exercises, targeting abdominal muscles, to be performed daily from postoperative day one to 2 months postsurgery.
Study: NCT03577457

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intranasal placebo treatment (placebo-control for oxytocin)
Description: intranasal administration of placebo nasal spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral placebo treatment (placebo-control for ATD)
Description: oral administration of a tryptophan-balanced mixture (78.2g)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oral placebo treatment (placebo-control for ATD)
Description: oral administration of a tryptophan-balanced mixture (78.2g)
Study: NCT03346837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986205
Description: BMS-986205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986205
Description: BMS-986205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986205
Description: BMS-986205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986205
Description: BMS-986205
Study: NCT03492463

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo patch
Description: Participants will wear the placebo patch daily while switching from cigarette use to use of e-cigarettes for eight weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: E-cigarettes
Description: Participants will use e-cigarettes containing nicotine while switching from cigarette use to use of e-cigarettes for eight weeks.
Study: NCT03346837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Tablet
Study: NCT03984240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Participant will be sedated by midazolam.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Participant will be sedated by midazolam.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Participant will be sedated by dexmedetomidine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Participant will be sedated by dexmedetomidine.
Study: NCT02279056

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-help book for insomnia
Description: RCT comparing efficacy of a self-help book for insomnia and sleep hygiene advice in patients with co-morbid OSA and insomnia.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sleep hygiene advice
Description: RCT comparing efficacy of a self-help book for insomnia and sleep hygiene advice in patients with co-morbid OSA and insomnia.
Study: NCT03747367

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Insufficient Sleep
Study: NCT03416894

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: DBS offers the opportunity to insert electrodes into deep brain structures and electrically stimulate them in a titratable and ultimately reversible manner
Study: NCT01019941

Intervention type: DRUG
Group type: OTHER
Intervention: CKD-810, Taxotere inj.
Description: Patients will receive docetaxel 75mg/㎡ on Day 1 of each cycle(1 cycle = 3 weeks) as a 1-hour IV infusion. At the 1st cycle, CKD-810 75mg/㎡ administered. If the hematologic or non-hematologic toxicity was not appeared when the 1st cycle intervention was finished, keep going the 2nd cycle intervention.

Intervention type: DRUG
Group type: OTHER
Intervention: CKD-810, Taxotere inj.
Description: Patients will receive docetaxel 75mg/㎡ on Day 1 of each cycle(1 cycle = 3 weeks) as a 1-hour IV infusion. At the 1st cycle, Taxotere inj. 75mg/㎡ administered. If the hematologic or non-hematologic toxicity was not appeared when the 1st cycle intervention was finished, keep going the 2nd cycle intervention.
Study: NCT03622151

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Primer la Llar program
Description: Housing First model: permanent housing without previous requirements such as abstinence, sobriety or compliance with treatment.
Study: NCT04838067

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cefaly
Description: Transcutaneous trigeminal nerve electrical neuromodulation
Study: NCT03492463

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: E-cigarettes
Description: Participants will use e-cigarettes containing nicotine while switching from cigarette use to use of e-cigarettes for eight weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-nicotine e-cigarettes
Description: Participants will use e-cigarettes not containing nicotine while switching from cigarette use to use of e-cigarettes for eight weeks.
Study: NCT00758563

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluoride
Description: Brush twice daily
Study: NCT01329328

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vibrating platform (Bioplate RF)
Description: whole body vibration exercise with multiple positions, with or without localized delivery of heating radiofrequency

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vibrating platform (Bioplate RF)
Description: whole body vibration exercise with multiple positions, with or without localized delivery of heating radiofrequency
Study: NCT00996372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flibanserin
Description: patients will be randomized to flibanserin or placebo in a double-blind manner

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: patients will be randomized to flibanserin or placebo in a double-blind manner
Study: NCT02313844

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Viralym-B
Description: Follow-up Assessments: The timing of follow-up visits is based on the date of Viralym-B infusion. If a patient has multiple Viralym-B infusions the schedule resets again at the beginning so follow up relates to the last Viralym-B infusion.~Follow up will occur at 7 days, 14 days, 21 days, 28 days, 42 days, 90 days, 180 days, and 365 days post enrollment.
Study: NCT02280655

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Storage-aged red blood cells (saRBCs) units
Description: Packed RBCs units stored for greater than 21 days, with a mean storage duration of 29.6 ± 4.9 days (mean ± SD)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fresh red blood cells units
Description: Packed RBCs units stored for less than 14 days, with a mean storage duration of 9.6 ± 3.9 days (mean ± SD)
Study: NCT00698802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EX1000
Description: Treat-to-target titration scheme, s.c. injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic human insulin
Description: Treat-to-target titration scheme, s.c. injection
Study: NCT02422121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RNS60

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo